Published in Health Insurance Week, May 1st, 2005
The company has identified a number of sites for the clinical study. The first implants of the Libra IPG System are anticipated to occur in the second quarter of this year.
The company also announced the submission to the FDA of an amendment to its IDE application to investigate the ANS Libra DBS System to treat Parkinson disease. ANS anticipates receiving this...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Insurance Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.